172478-01-2

Basic information

• Product Name: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE
• Synonyms: 3-N-BOC-3-N-METHYLAMINO PIPERIDINE;3-N-BOC-3-(METHYLAMINO)PIPERIDINE;METHYL-PIPERIDIN-3-YL-CARBAMIC ACID TERT-BUTYL ESTER;tert-butyl methyl(piperidin-3-yl)carbamate;3-(N-Boc-N-methyl)aminopiperidine;3-Boc-3-MethylaMinopiperidine;3-N-Boc-3-(MethylaMino)pi...;tert-butyl N-methyl-N-(piperidin-3-yl)carbamate
• CAS NO: 172478-01-2
• Molecular Formula: C₁₁H₂₂N₂O₂
• Molecular Weight: 214.3
• Product Categories: Amines;Pyrans, Piperidines &Piperazines;Pyrans, Piperidines & Piperazines
• Mol File: 172478-01-2.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 287.863 °C at 760 mmHg
• Flash Point: 127.895 °C
• Appearance: /
• Density: 1.019 g/cm³
• Vapor Pressure: 0.00242mmHg at 25°C
• Refractive Index: 1.485
• Storage Temp.: 2-8°C(protect from light)
• PKA: 9.74±0.10(Predicted)
• CAS DataBase Reference: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE(172478-01-2)
• EPA Substance Registry System: 3-N-BOC-3-(METHYLAMINO)PIPERIDINE(172478-01-2)

Safety Data

• Hazardous Substances Data: 172478-01-2(Hazardous Substances Data)

Usage

General Description

3-N-BOC-3-(Methylamino)piperidine is a chemical substance that belongs to the class of organic compounds known as piperidines. Piperidines are compounds containing a piperidine ring, which is a saturated aliphatic six-member ring with one nitrogen atom and five carbon atoms. In the case of 3-N-BOC-3-(Methylamino)piperidine, it contains a methylamino group, which is a primary aliphatic amine functional group, and a BOC group (tert-butyloxycarbonyl), which is a protecting group used in organic synthesis. The exact properties and applications of this chemical may vary depending on its specific structure and form, and it should be handled with appropriate safety measures as with any chemical substance.

InChI:InChI=1/C11H22N2O2/c1-11(2,3)15-10(14)13(4)9-6-5-7-12-8-9/h9,12H,5-8H2,1-4H3

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 18364-47-1 N-methyl-N-(3-pyridyl)amine 
• 406213-47-6 3-t-butoxycarbonylaminopiperidin-1-carboxylic acid benzyl ester 
• 74-88-4 methyl iodide 
• 1279817-03-6 pyridin-3-ylmethyl-carbamic acid tert-butyl ester 
• 60717-45-5 1-benzyl-N-methylpiperidin-3-amine 
• 40114-49-6 1-benzyl-3-piperidone 
• 172477-99-5 1-benzyl-3-<(t-butyloxycarbonyl)methylamino>-piperidine 

Downstream Products

• 172478-05-6 3-methylamino-1-propionyl-piperidine 

Relevant articles and documents

SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

1,3-DIHYDROIMIDAZOLE FUSED-RING COMPOUND

The objective of this invention is to provide novel compounds that show excellent DPPIV-inhibiting activity. The present invention provides compounds represented by the general formula (I), salts thereof, or hydrates thereof, [wherein,T1 stands for a monocyclic or bicyclic 4 to 12-membered heterocycle having 1 or 2 nitrogen atoms in the ring, which may have substituents; in formula (I), the following formula represents a double bond or a single bond; X3 denotes an oxygen atom or a sulfur atom; X1 denotes a C2-6 alkynyl group which may have substituents; Z1 denotes a nitrogen atom or the formula -CR3=; Z2 and Z3 each independently denote a nitrogen atom, the formula -CR1=, a carbonyl group, or the formula -NR2-; R1, R2, R3, and X2 each independently denote a C1-6 alkyl group which may have substituents, and such].

Condensed imidazole derivatives

The present invention is related to compounds represented by the following formula, or salts or hydrates thereof wherein, T1 represents a 4- to 12-membered heterocyclic group containing one or two nitrogen atoms in the ring, which is a monocyclic or bicyclic structure that may have one or more substituents; X represents a C1-6 alkyl group which may have one or more substituents, or such; Z1 and Z2 each independently represent a nitrogen atom or a group represented by the formula —CR2—; R1 and R2 independently represent a hydrogen atom, a C1-6 alkyl group which may have one or more substituents, or a C1-6 alkoxy group which may have one or more substituents, or such. These are novel compounds that exhibit an excellent DPPIV-inhibiting activity.